Arbutus Biopharma Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Arbutus Biopharma Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 64%
Sales fell 64% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-64% / -52%In 3 years sales changed by -64% while total assets changed by -52%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-72.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 78% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 56% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Arbutus Biopharma Corporation owes $0.06 for every $1 it owns. Arbutus Biopharma Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
5.3Investors pay $5.3 for every $1 of Arbutus Biopharma Corporation's yearly profit, lower than 85% of Healthcare companies in United States.
P/B ratio
2.49The share price is 2.49 times Arbutus Biopharma Corporation's book value per share, lower than 51% of Healthcare companies in United States.
Market cap
$645 MThe total market value of all of Arbutus Biopharma Corporation's shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$259 MWhat Arbutus Biopharma Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.69Net worth divided by the number of shares. The share price of $4.21 is 2.5 times this, which is the P/B above.
Return on equity (ROE)
89.6%Arbutus Biopharma Corporation earned 89.6% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
Owes vs Owns
0.06×Arbutus Biopharma Corporation owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneArbutus Biopharma Corporation does not currently pay a dividend.
Revenue growth
+128%Revenue rose 128% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Profit growth
LossArbutus Biopharma Corporation made a loss in each of the last two years.
Profit margin
-237.9%Arbutus Biopharma Corporation lost $238 for every $100 of revenue.
Interest cover
Not coveredArbutus Biopharma Corporation's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashArbutus Biopharma Corporation held $91 M more cash than debt (net cash) at Dec 2025.
Questions
What is Arbutus Biopharma Corporation's P/E ratio?
Investors pay $5.3 for every $1 of Arbutus Biopharma Corporation's yearly profit, lower than 85% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Arbutus Biopharma Corporation: $645 M ÷ $259 M (30 Jun 2026) = 2.5.
What is Arbutus Biopharma Corporation's return on equity?
Arbutus Biopharma Corporation earned 89.6% on its shareholders' money over the last year, higher than 98% of Healthcare companies in United States.
How much does Arbutus Biopharma Corporation owe compared with what it owns?
Arbutus Biopharma Corporation owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Arbutus Biopharma Corporation pay a dividend?
No. Arbutus Biopharma Corporation does not currently pay a dividend.
Is Arbutus Biopharma Corporation's revenue growing?
Revenue rose 128% in the year to Dec 2025, and shrank 29% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.